Search Results - Judit Demeter

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption by Judit Demeter, Julia Weisinger, Zsolt Nagy

    Get full text
    Article


  2. 2

    Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary by Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Zsolt Abonyi-Toth, Judit Demeter

    Published in Pathology and Oncology Research (2024-02-01)
    Get full text
    Article


  3. 3

    Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungar... by Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Zsolt Abonyi-Toth, Judit Demeter

    Published in Pathology and Oncology Research (2024-03-01)
    Get full text
    Article


  4. 4

    Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology... by Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Published in Pathology and Oncology Research (2023-11-01)
    Get full text
    Article


  5. 5

    Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A by Kata Ferenczi, Zsófia Flóra Nagy, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Published in Pathology and Oncology Research (2025-05-01)
    Get full text
    Article


  6. 6

    Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia by Zsófia F. Nagy, Kata Ferenczi, Ildikó Istenes, Hanna Eid, Csaba Bödör, Botond Timár, Judit Demeter

    Published in Pathology and Oncology Research (2022-04-01)
    Get full text
    Article


  7. 7

    Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival by Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy

    Published in Journal of Advanced Research (2019-11-01)
    Get full text
    Article


  8. 8

    Case report: Comprehensive clinical, pathological and genetic investigations to decipher the background of cyclic thrombocytopenia by Zsófia Flóra Nagy, Kristóf Árvai, Péter Lakatos, Ildikó Beke Debreceni, Balázs Szili, Ildikó Istenes, Csaba Bödör, Judit Demeter

    Published in Pathology and Oncology Research (2024-09-01)
    Get full text
    Article


  9. 9

    Case Report: Importance of high-throughput genetic investigations in the differential diagnosis of unexplained erythrocytosis by Zsófia Flóra Nagy, György Pfliegler, János Kósa, Kristóf Árvai, Ildikó Istenes, Attila Doros, Botond Timár, Péter Lakatos, Judit Demeter

    Published in Pathology and Oncology Research (2025-03-01)
    Get full text
    Article


  10. 10

    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study by Christopher R. Flowers, Matthew J. Matasar, Alex F. Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný, Lisa Musick, Jamie Hirata, Annie Yang, Laurie H. Sehn

    Published in Haematologica (2023-09-01)
    Get full text
    Article


  11. 11

    Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry by Ferenc Takács, Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna

    Published in Pathology and Oncology Research (2022-09-01)
    Get full text
    Article


  12. 12

    P1245: PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA by Bence Bátai, Ákos Nagy, Laura Kiss, Stefánia Gróf, Péter Attila Király, Ádám Jóna, Judit Demeter, Hermina Santa, Arpad Batai, Piroska Pettendi, Tamás Szendrei, Márk Béla Plander, Gábor Kőrösmezey, Hussain Alizadeh, Béla Kajtár, Gábor Méhes, László Krenács, Botond Timár, Judit Csomor, Erika Tóth, Tamás Schneider, Gabor Mikala, András Matolcsy, Donat Alpar, András Masszi, Csaba Bödör

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  13. 13

    Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial by Hartmut Döhner, Argiris Symeonidis, Dries Deeren, Judit Demeter, Miguel A. Sanz, Achilles Anagnostopoulos, Jordi Esteve, Walter Fiedler, Kimmo Porkka, Hee-Je Kim, Je-Hwan Lee, Kensuke Usuki, Stefano D'Ardia, Chul Won Jung, Olga Salamero, Heinz-August Horst, Christian Recher, Philippe Rousselot, Irwindeep Sandhu, Koen Theunissen, Felicitas Thol, Konstanze Döhner, Veronica Teleanu, Daniel J. DeAngelo, Tomoki Naoe, Mikkael A. Sekeres, Valerie Belsack, Miaomiao Ge, Tillmann Taube, Oliver G. Ottmann

    Published in HemaSphere (2021-08-01)
    Get full text
    Article


  14. 14

    PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION by Tamás László, Lili Kotmayer, Lajos Hegyi, Stefánia Gróf, Béla Kajtár, Alexandra Balogh, Júlia Weisinger, Tamás Masszi, Zsolt Nagy, Judit Demeter, Péter Farkas, Ildikó Istenes, Róbert Szász, Lajos Gergely, Adrienn Sulák, Zita Borbényi, Dóra Lévai, Tamás Schneider, Erika Szaleczky, Piroska Pettendi, Emese Bodai, László Szerafin, László Rejtő, Árpád Bátai, Mária Ágnes Dömötör, Hermina Sánta, Márk Plander, Tamás Szendrei, Péter Ilonczai, Aryan Hamed, Zsolt Lázár, Zsolt Pauker, Gáspár Radványi, Adrienn Kiss, Gábor Körösmezey, János Jakucs, Péter János Dombi, Zsófia Simon, Zsolt Klucsik, Mihály Gurzó, Márta Tiboly, Tímea Vidra, András Bors, Hajnalka Andrikovics, Miklós Egyed, Tamás Székely, András Masszi, András Matolcsy, Donát Alpár, Csaba Bödör

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  15. 15

    Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation by Tamás László, Lili Kotmayer, Viktória Fésüs, Lajos Hegyi, Stefánia Gróf, Ákos Nagy, Béla Kajtár, Alexandra Balogh, Júlia Weisinger, Tamás Masszi, Zsolt Nagy, Péter Farkas, Judit Demeter, Ildikó Istenes, Róbert Szász, Lajos Gergely, Adrienn Sulák, Zita Borbényi, Dóra Lévai, Tamás Schneider, Piroska Pettendi, Emese Bodai, László Szerafin, László Rejtő, Árpád Bátai, Mária Á Dömötör, Hermina Sánta, Márk Plander, Tamás Szendrei, Aryan Hamed, Zsolt Lázár, Zsolt Pauker, Gáspár Radványi, Adrienn Kiss, Gábor Körösmezey, János Jakucs, Péter J Dombi, Zsófia Simon, Zsolt Klucsik, Mihály Gurzó, Márta Tiboly, Tímea Vidra, Péter Ilonczai, András Bors, Hajnalka Andrikovics, Miklós Egyed, Tamás Székely, András Masszi, Donát Alpár, András Matolcsy, Csaba Bödör

    Get full text
    Article


Search Tools: